Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats

Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats

AbstractRepaglinide (RPG), a monotherapy insulin secretagogue used to treat diabetes mellitus-type II yet, it suffers from poor water solubility and variable bioavailability (∼ 50%) due to hepatic first pass metabolism. In this study, 2FI I-Optimal statistical design was employed to encapsulate RPG...

Full description

Bibliographic Details
Main Authors: Shahinaze A. Fouad, Mahmoud H. Teaima, Mostafa I. Gebril, Fathy I. Abd Allah, Mohamed A. El-Nabarawi, Sammar Fathy Elhabal
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Drug Delivery
Subjects:
Diabetes mellitus (type II)
repaglinide
niosomes
coprocessed excipients
dysphagia
chewable tablets
Online Access:https://www.tandfonline.com/doi/10.1080/10717544.2023.2181747

Internet

https://www.tandfonline.com/doi/10.1080/10717544.2023.2181747

Similar Items